ClearMed
All Nephrology BriefingsKidney International
NephrologyPreclinical3 min read

Are we ready for the widespread application of transcutaneous measurement of the glomerular filtration rate?

Accurate assessment of glomerular filtration rate is central to renal evaluation in clinical and preclinical settings.

Published in Kidney InternationalLaboratory research
2/5 Preclinical
Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

Source

Animal & Preclinical Data

2/5

The observations by Shimada et al. highlight both the promise and limitations of transcutaneous glomerular filtration rate, particularly in conditions that affect distribution volume, underscoring the need for rigorous evaluation across diverse physiological and disease states.

What Changes?

Nephrology · Preclinical

Current Standard

Existing nephrology care has lacked direct translational evidence targeting glomerular filtration & renal tubular preservation.

New Finding

Transcutaneous glomerular filtration rate offers practical advantages over conventionally measured glomerular filtration rate, including minimally invasive and continuous monitoring, but requires robust validation.

3 Key Takeaways

Plain English Summary
  1. 01Core Finding

    Delivered via are we ready for the widespread application of transcutaneous measurement of the, this preclinical approach targets Glomerular filtration & renal tubular preservation.

  2. 02Study Evidence

    Tested in a laboratory experimental model (preclinical discovery) at the preclinical stage.

  3. 03Practical Meaning

    Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.

What This Means for You

The observations by Shimada et al. highlight both the promise and limitations of transcutaneous glomerular filtration rate, particularly in conditions that affect distribution volume, underscoring the need for rigorous evaluation across diverse physiological and disease states.

The Discovery

Accurate assessment of glomerular filtration rate is central to renal evaluation in clinical and preclinical settings. Transcutaneous glomerular filtration rate offers practical advantages over conventionally measured glomerular filtration rate, including minimally invasive and continuous monitoring, but requires robust validation.

How It Works, Simply

This nephrology research focuses on glomerular filtration & renal tubular preservation. Researchers evaluated it using a laboratory experimental model (Preclinical discovery) at the preclinical stage of medical research.

3 Key Takeaways

Clinical Takeaways
  1. 01Core Finding

    Delivered via are we ready for the widespread application of transcutaneous measurement of the, this preclinical approach targets Glomerular filtration & renal tubular preservation.

  2. 02Study Evidence

    Tested in a laboratory experimental model (preclinical discovery) at the preclinical stage.

  3. 03Practical Meaning

    Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.

01

Biological Mechanism & Study Design

Study Design & Cohort

Laboratory research

Laboratory experimental model (Preclinical discovery) · Preclinical

Biological Pathway & Modality

Glomerular filtration & renal tubular preservation

Intervention: Are we ready for the widespread application of transcutaneous measurement of the

02

Experimental Findings & Endpoints

Accurate assessment of glomerular filtration rate is central to renal evaluation in clinical and preclinical settings.

Transcutaneous glomerular filtration rate offers practical advantages over conventionally measured glomerular filtration rate, including minimally invasive and continuous monitoring, but requires robust validation.

03

Clinical Translation & Practice Context

The observations by Shimada et al. highlight both the promise and limitations of transcutaneous glomerular filtration rate, particularly in conditions that affect distribution volume, underscoring the need for rigorous evaluation across diverse physiological and disease states.

03

The Bottom Line · Clinical Pearl

“The observations by Shimada et al. highlight both the promise and limitations of transcutaneous glomerular filtration rate, particularly in conditions that affect distribution volume, underscoring the need for rigorous evaluation across diverse physiological and disease states.”

Published in Kidney International · Current Stage: Preclinical

Nephrology · Preclinical
Study Type
Laboratory research

Laboratory experimental model (Preclinical discovery)

Evidence Score
2/5 · Animal & Preclinical Data
Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

Who It Applies To
Preclinical research (Laboratory experimental model (Preclinical discovery)) — not yet tested in human patients
Intervention & Mechanism
Are we ready for the widespread application of transcutaneous measurement of the

Glomerular filtration & renal tubular preservation

Key Limitation
Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.

Translational Stage

LEVEL 3 · Preclinical

Classified as Laboratory research along the clinical evidence continuum

  1. 1PreclinicalActive
  2. 2Early Trials
  3. 3Human Evidence
  4. 4Meta & Practice

Indexed Clinical Entities

Original Publication & AMA Citation

Are we ready for the widespread application of transcutaneous measurement of the glomerular filtration rate?. Kidney International. Published 2026;Nov 10. Accessed November 15, 2026. https://pubmed.ncbi.nlm.nih.gov/42901685/

Kidney International

https://pubmed.ncbi.nlm.nih.gov/42901685/

Read Original Paper

Continue Reading

Related in Nephrology

View all Nephrology briefings →
NEPHROLOGY · PRECLINICAL

Gut-targeted interventions to complement PTH-lowering therapy

These findings highlight the potential of gut-targeted interventions to complement established parathyroid hormone-lowering strategies for improving skeletal health. Secondary hyperparathyroidism is a major contributor to skeletal fragility in chronic kidney disease, yet fracture risk remains high despite parathyroid hormone-lowering therapy.

2/5 Preclinical
Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readKidney International
NEPHROLOGY · PHASE I/II

Fingerprinting the polycystic kidney: radiomics of the noncystic parenchyma for earlier ADPKD detection

Small, cross-sectional, unmatched data require longitudinal validation of reproducibility, prognostic value, and clinical utility. Autosomal dominant polycystic kidney disease risk stratification relies on total kidney volume, a validated marker of cyst burden and progression.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney International
NEPHROLOGY · CLINICAL PRACTICE

Kidney stone disease: to drink or not to drink-that is the question

Effective prevention likely requires achieving a substantial increase in urine volume alongside comprehensive dietary and pharmacologic management. An important point to note is that these findings do not invalidate the protective role of increased urine volume but highlight the limitations of behavioral interventions alone.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney International